ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value...

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics...

Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and ProfitabilityCompany in Late-Stage Discussions with Two Additional Large Global Brands...

ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output. Pharmaloz plan is to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by year-end 2024, with 20-25% pre-tax net margins and a goal for additional growth thereafter. ...

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023 Company believes that the combined value of its five operating units exceeds its current market capitalization and that each unit has significant growth potential. Company highlights...